Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers

41Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Cysteine-rich intestinal protein 1 (CRIP1) has been identified as a novel marker for early detection of cancers. Here we report on the use of phage display in combination with molecular modeling to identify a high-affinity ligand for CRIP1. Panning experiments using a circularized C7C phage library yielded several consensus sequences with modest binding affinities to purified CRIP1. Two sequence motifs, A1 and B5, having the highest affinities for CRIP1, were chosen for further study. With peptide structure information and the NMR structure of CRIP1, the higher-affinity A1 peptide was computationally redesigned, yielding a novel peptide, A1M, whose affinity was predicted to be much improved. Synthesis of the peptide and saturation and competitive binding studies demonstrated approximately a 10-28-fold improvement in the affinity of A1M compared to that of either A1 or B5 peptide. These techniques have broad application to the design of novel ligand peptides. © 2008 Hao et al.

Cite

CITATION STYLE

APA

Hao, J., Serohijos, A. W. R., Newton, G., Tassone, G., Wang, Z., Sgroi, D. C., … Basilion, J. P. (2008). Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Computational Biology, 4(8). https://doi.org/10.1371/journal.pcbi.1000138

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free